Global Dengue Testing Market is expected to reach $XX Mn by 2026 from $XX Mn in 2019, at a CAGR of 5.5% during forecast period.
Global Dengue Testing Market Overview:
Dengue fever is a mosquito-borne disease that affects people. ELISA or PCR-based blood tests are the most frequent methods for diagnosing the dengue virus. Rapid point-of-care assays, which have recently been developed, allow for early detection and notification of the disease.
Global Dengue Testing Market Dynamics:
Rising cases of Dengue fever every year boosts the market growth.
An increase in the prevalence of dengue fever and increased awareness initiatives to teach about the afflictions of dengue are driving the growth of the worldwide dengue virus diagnostic testing market. In recent years, the number of cases of dengue fever has risen dramatically. Africa, the Americas, the Eastern Mediterranean, Southeast Asia, and the Western Pacific are the major dengue-affected regions in the world. Around 500,000 of these cases progress to dengue haemorrhagic fever or severe dengue, a more severe form of the disease that causes up to 25,000 deaths worldwide each year.
The demand for cost-efficient test kits with high specificity and sensitivity is driven by a lack of effective diagnostic tools and the high cost of existing test kits. As a result, firms in this market are currently concentrating on the development of cost-effective and reliable dengue diagnostic technologies. Climate change is projected to increase the prevalence of dengue fever, which will fuel the growth of the dengue testing market. Despite the high level of awareness of dengue prevention and treatment, there are a number of hurdles, including insufficient financing and resources, as well as a lack of a clear plan to address the growing difficulties associated with dengue epidemics in many parts of the world. Rapid urbanization, a lack of sanitation, increased international trade, and population movement stifles efforts to reduce pollution.
The report has profiled seventeen key players in the market from different regions. However, report has considered all market leaders, followers and new entrants with investors while analyzing the market and estimation the size of the same. Increasing R&D activities in each region are different and focus is given on the regional impact on the cost, availability of advanced technology are analyzed and report has come up with recommendations for future hot spot in APAC region.
Global Dengue Testing Market Segment Analysis:
The Global Dengue Testing Market is segmented on the basis of Test Type and End-Users.
Based on Test Type, the ELISA-based segment is expected to account for dominant market share during the forecast period. An enzyme-linked immunosorbent test (ELISA), which analyses anti-DENV IgM or IgG antibodies in patient serum, is the most extensively used approach for diagnosing dengue fever. Early detection and treatment of dengue fever help to lower morbidity and fatality rates associated with severe forms of the disease, as well as the danger of larger outbreaks. In 2020, the EIA/ELISA category dominated the immunoassay market, with a revenue share of 63.7%. Reduced test time, quantitative results, and the use of less antisera for analysis are some of the key advantages of this technology over Immunoelectrophoresis and immunodiffusion.
Furthermore, due to new product introductions, technological developments, and accuracy, RT-PCR testing is expected to rise at a significant rate. For example, in April 2019, Beroni Group Limited and Columbia University inked an exclusive license agreement under which Columbia University granted Beroni and its affiliates worldwide distribution rights to the patented CII-ArboViroPlex rRT-PCR assay.
Global Dengue Testing Market
To know about the Research Methodology :- Request Free Sample Report
Global Dengue Testing Market Regional Insights:
Global Dengue Testing Market 1
APAC is expected to account for significant market share during forecast period.
Because there are millions of instances of dengue infection each year, Asia Pacific is determined to be leading in the worldwide dengue testing market. Since 2009, the number of dengue cases in India has increased gradually, and the total number of deaths in 2017 was the most in the prior decade. Dengue fever is most prevalent in Southeast Asia, and the disease is on the rise. As a result of the rising frequency of infectious diseases, especially dengue fever, in India, Pakistan, and Sri Lanka, the market for dengue testing in the Asia Pacific is rapidly growing. There were 3.1 million instances in the American region alone, with over 25,000 of them categorized as severe. Despite the frightening number of infections, dengue-related mortality was down from the previous year.
The report also helps in understanding Global Dengue Testing Market dynamics, structure by analyzing the market segments and project the Global Dengue Testing Market size. Clear representation of competitive analysis of key players by product, price, financial position, product portfolio, growth strategies, and regional presence in the Global Dengue Testing Market make the report investor’s guide.
Global Dengue Testing Market Scope: Inquire before buying
Global Dengue Testing Market 3
Global Dengue Testing Market, By Region:
• North America
• Europe
• South America
• MEA
• APAC
Global Dengue Testing Market, Key players:
• Thermo Fisher Scientific Inc.
• Roche Molecular Systems Inc.
• Abbott Laboratories
• Abnova Corporation
• InBios International, Inc.
• NovaTec Immundiagnostica GmbH
• Euroimmun AG (Sub. PerkinElmer)
• Quest Diagnostics
• Certest Biotec S.L.
• OriGene Technologies
• Arkray Inc.
• Ceres Nanosciences Inc.
• Corgenix Medical Corp
• FK-Biotecnologia SA
• QuantuMDx Group Ltd.
• Sansure Biotech Inc.
• Quidel Corp
